INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
Open accessAbstract
The INK4a/ARF locus encodes upstream regulators of the retinoblastoma and p53 tumor suppressor gene products. To compare the impact of these loci on tumor development and treatment response, the Emu-myc transgenic lymphoma model was used to generate genetically defined tumors with mutations in the INK4a/ARF, Rb, or p53 genes. Like p53 null lymphomas, INK4a/ARF null lymphomas formed rapidly, were highly invasive, displayed apoptotic defects, and were markedly resistant to chemotherapy in vitro and in vivo. Furthermore, INK4a/ARF(-/-) lymphomas displayed reduced p53 activity despite the presence of wild-type p53 genes. Consequently, INK4a/ARF and p53 mutations lead to aggressive tumors by disrupting overlapping tumor suppressor functions. These data have important implications for understanding the clinical behavior of human tumors.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Under stress such as oncogene activation, loss of Arf leaves Mdm2 deregulated and prevents effective p53 activation.
“However, under stressful conditions, such as when oncogenes are activated, loss of Arf results in deregulated Mdm2 and the inability of a cell to effectively activate p53 (Eischen, et al., 1999; Schmitt, et al., 1999; Zindy, et al., 1998).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Schmitt, et al., 1999
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,178 · cited 1× · see citing works
“…protein that can induce cell-cycle arrest or apoptosis in response to pathological insults such as DNA damage and expression of mitogenic oncogenes (Kastan et al. 1991, 1992; Lowe and Ruley 1993; Hermeking and Eick 1994; Serrano et al. 1997; for reviews, see Giaccia and Kastan 1998; Prives 1998).”
BackgroundSelf-citationParticipation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761 · see citing works
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · see citing works
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · see citing works
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,911 · see citing works
Self-citationTumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051 · see citing works
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,778 · see citing works
Effects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755 · see citing works
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626 · see citing works
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · see citing works
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566 · see citing works
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · see citing works
The complexity of p53 modulation: emerging patterns from divergent signalsPreprint
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,303 · see citing works
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245 · see citing works
Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K. M., Hara, E., Vousden, K. H., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,165 · see citing works
Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARFPreprint
Jacobs, J. J. L., Scheijen, B., Voncken, J. W., Kieboom, K., Berns, A. J. M., & van Lohuizen, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2678 · Cited by 1,060 · see citing works
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · see citing works
Nucleolar Arf sequesters Mdm2 and activates p53
Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., & Bar-Sagi, D. (1999) · Nature Cell Biology · doi:10.1038/8991 · Cited by 940 · see citing works
p14ARF links the tumour suppressors RB and p53
Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., & Vousden, K. H. (1998) · Nature · doi:10.1038/25867 · Cited by 918 · see citing works
The p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911 · see citing works
Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2
Strasser, A., Harris, A. W., Bath, M. L., & Cory, S. (1990) · Nature · doi:10.1038/348331a0 · Cited by 905 · see citing works
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., & Sherr, C. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8292 · Cited by 899 · see citing works
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819 · see citing works
Mediation of c-Myc-Induced Apoptosis by p53
Hermeking, H., & Eick, D. (1994) · Science · doi:10.1126/science.8091232 · Cited by 738 · see citing works
Tumor surveillance via the ARF–p53 pathwayPreprint
Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.19.2984 · Cited by 716 · see citing works
Apoptosis, p53, and tumor cell sensitivity to anticancer agents.
Brown, J. M., & Wouters, B. G. (1999) · PubMed · Cited by 696 · see citing works
Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.Preprint
Lowe, S. W., & Ruley, H. E. (1993) · Genes & Development · doi:10.1101/gad.7.4.535 · Cited by 662 · see citing works
Self-citationPrives, C. (1998) · Cell · doi:10.1016/s0092-8674(00)81774-2 · Cited by 623 · see citing works
p19ARF links the tumour suppressor p53 to Ras
Palmero, I., Pantoja, C., & Serrano, M. (1998) · Nature · doi:10.1038/25870 · Cited by 617 · see citing works
E1A signaling to p53 involves the p19ARFtumor suppressorPreprint
de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S.-Y., Ferbeyre, G., Samuelson, A. V., Prives, C. L., Roussel, M. F., Sherr, C. J., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.15.2434 · Cited by 607 · see citing works
Self-citationWattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 592 · see citing works
P19 ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2
Tao, W., & Levine, A. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6937 · Cited by 539 · see citing works
Fan, S., El‐Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K. G., Fornace, A. J., MAGRATH, I. T., Kohn, K. W., & O'Connor, P. M. (1994) · PubMed · Cited by 404 · see citing works
Rouby, S. E., Thomas, A., Costin, D., et al. (1993) · Blood · doi:10.1182/blood.v82.11.3452.3452 · Cited by 366 · see citing works
Zhang, Y., & Xiong, Y. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80351-2 · Cited by 347 · see citing works
Clinical implications of p53 mutations
Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050270 · Cited by 223 · see citing works
Self-citationWilson, W. H., Teruya‐Feldstein, J., Fest, T., Harris, C. A., Steinberg, S. M., Jaffe, E. S., & Raffeld, M. A. (1997) · Blood · doi:10.1182/blood.v89.2.601 · Cited by 221 · see citing works
p53 gene mutation: software and database
Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 187 · see citing works
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149 · see citing works
Splicing into Senescence: The Curious Case of p16 and p19ARF
Haber, D. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80441-9 · Cited by 144 · see citing works
Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia
Diccianni, M. B., Yu, A. L.-T., Hsiao, M., Mukherjee, S., Shao, L.-E., & Yu, A. L.-T. (1994) · Blood · doi:10.1182/blood.v84.9.3105.3105 · Cited by 123 · see citing works
Xiong, Y., Yarbrough, W. G., & Zhang, Y. (2021) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/rwgt-6m22 · Cited by 88 · see citing works
Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis.
Hsu, B., Marín, M. C., El‐Naggar, A. K., Stephens, L. C., Brisbay, S. M., & McDonnell, T. J. (1995) · PubMed · Cited by 83 · see citing works
Wattel, E., Preudhomme, C., Hecquet, B., et al. (1994) · Blood · doi:10.1182/blood.v84.9.3148.bloodjournal8493148 · Cited by 58 · see citing works
Transgenic models for haemopoietic malignancies
Adams, J. M., & Cory, S. (1991) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(91)90004-5 · Cited by 37 · see citing works
Rouby, S. E., Thomas, A., Costin, D., et al. (1993) · Blood · doi:10.1182/blood.v82.11.3452.bloodjournal82113452 · Cited by 32 · see citing works
Zhang, Y., & Xiong, Y. (2021) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/mj7p-9v31 · Cited by 18 · see citing works
Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia
Diccianni, M. B., Yu, J., Hsiao, M., et al. (1994) · Blood · doi:10.1182/blood.v84.9.3105.bloodjournal8493105 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · see citing works
Oncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220 · see citing works
Self-citationSenescence-associated reprogramming promotes cancer stemness
Milanovic, M., Fan, D. N. Y., Belenki, D., Däbritz, J. H. M., Zhao, Z., Yu, Y., Dörr, J. R., Dimitrova, L., Lenze, D., Monteiro Barbosa, I. A., et al. (2018) · Nature · doi:10.1038/nature25167 · Cited by 1,131 · see citing works
Self-citationChien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J. E., Premsrirut, P., Luo, W., Chicas, A., Lee, C. S., et al. (2011) · Genes & Development · doi:10.1101/gad.17276711 · Cited by 1,046 · see citing works
Self-citationA Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050 · see citing works
Self-citationDisruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819 · see citing works
Tumor suppression by Ink4a-Arf: progress and puzzles.
Lowe, S. W., & Sherr, C. J. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00013-8 · Cited by 699 · see citing works
Self-citationSherr, C. J., & Weber, J. D. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00038-6 · Cited by 654 · see citing works
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · see citing works
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A. (2001) · Nature · doi:10.1038/35092584 · Cited by 568 · see citing works
Fisher, G. H., Wellen, S. L., Klimstra, D., Lenczowski, J. M., Tichelaar, J. W., Lizak, M. J., Whitsett, J. A., Koretsky, A., & Varmus, H. E. (2001) · Genes & Development · doi:10.1101/gad.947701 · Cited by 582 · see citing works
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
Dörr, J. R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J. H. M., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., et al. (2013) · Nature · doi:10.1038/nature12437 · Cited by 541 · see citing works
Self-citationDistinct Thresholds Govern Myc's Biological Output In Vivo
Murphy, D. J., Junttila, M. R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D. A., Brown-Swigart, L., Johnson, L., & Evan, G. I. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.018 · Cited by 456 · see citing works
Tumor suppressors and oncogenes in cellular senescence
Bringold, F., & Serrano, M. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00083-8 · Cited by 379 · see citing works
Virus-induced senescence is a driver and therapeutic target in COVID-19
Lee, S., Yu, Y., Trimpert, J., Benthani, F., Mairhofer, M., Richter-Pechanska, P., Wyler, E., Belenki, D., Kaltenbrunner, S., Pammer, M., et al. (2021) · Nature · doi:10.1038/s41586-021-03995-1 · Cited by 350 · see citing works
Self-citationDAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation
Raveh, T., Droguett, G., Horwitz, M. S., DePinho, R. A., & Kimchi, A. (2001) · Nature Cell Biology · doi:10.1038/35050500 · Cited by 361 · see citing works
PML Is a Direct p53 Target that Modulates p53 Effector Functions
de Stanchina, E., Querido, E., Narita, M., Davuluri, R. V., Pandolfi, P. P., Ferbeyre, G., & Lowe, S. W. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00062-0 · Cited by 312 · see citing works
Self-citationSenescence, apoptosis and therapy — cutting the lifelines of cancer
Schmitt, C. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1044 · Cited by 295 · see citing works
Self-citationmTORC1 promotes survival through translational control of Mcl-1
Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804821105 · Cited by 285 · see citing works
Self-citationCellular senescence and cancer treatment
Schmitt, C. A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.005 · Cited by 254 · see citing works
Self-citationIntact p53-Dependent Responses in miR-34–Deficient Mice
Concepcion, C. P., Han, Y.-C., Mu, P., Bonetti, C., Yao, E., D'Andrea, A., Vidigal, J. A., Maughan, W. P., Ogrodowski, P., & Ventura, A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002797 · Cited by 197 · see citing works
Tumor Stroma-Derived TGF-β Limits Myc-Driven Lymphomagenesis via Suv39h1-Dependent Senescence
Reimann, M., Lee, S., Loddenkemper, C., Dörr, J. R., Tabor, V., Aichele, P., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.043 · Cited by 184 · see citing works
Self-citationTissue-specific and reversible RNA interference in transgenic mice
Dickins, R. A., McJunkin, K., Hernando, E., Premsrirut, P. K., Krizhanovsky, V., Burgess, D. J., Kim, S. Y., Cordon-Cardo, C., Zender, L., Hannon, G. J., et al. (2007) · Nature Genetics · doi:10.1038/ng2045 · Cited by 174 · see citing works
Self-citationDual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas
Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., & Chin, L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2144-2153.2001 · Cited by 166 · see citing works
Yu, Y., Schleich, K., Yue, B., Ji, S., Lohneis, P., Kemper, K., Silvis, M. R., Qutob, N., van Rooijen, E., Werner-Klein, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.002 · Cited by 156 · see citing works
Self-citationBrummelkamp, T. R., Kortlever, R. M., Lingbeek, M., Trettel, F., MacDonald, M. E., van Lohuizen, M., & Bernards, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110492200 · Cited by 154 · see citing works
Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis
Alt, J. R., Greiner, T. C., Cleveland, J. L., & Eischen, C. M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg133 · Cited by 129 · see citing works
Nilsson, L. M., Plym Forshell, T. Z., Rimpi, S., Kreutzer, C., Pretsch, W., Bornkamm, G. W., & Nilsson, J. A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002573 · Cited by 85 · see citing works
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79 · see citing works
Wang, Y. V., Leblanc, M., Wade, M., Jochemsen, A. G., & Wahl, G. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.008 · Cited by 79 · see citing works
De Clercq, S., Gembarska, A., Denecker, G., Maetens, M., Naessens, M., Haigh, K., Haigh, J. J., & Marine, J.-C. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00330-10 · Cited by 35 · see citing works
Essential Role of Phospholipase Cγ2 in Early B-Cell Development and Myc-Mediated Lymphomagenesis
Wen, R., Chen, Y., Bai, L., Fu, G., Schuman, J., Dai, X., Zeng, H., Yang, C., Stephan, R. P., Cleveland, J. L., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00839-06 · Cited by 34 · see citing works
- Authors
- Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W.
- Affiliations
- Cold Spring Harbor Laboratory (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 1999-10-15
- Volume
- 13
- Issue
- 20
- Pages
- 2670-2677
- ISSN
- 0890-9369 (ISSN-L)
- PMC
- PMC317110
- OpenAlex
- W2164559478
- Cited by
- 458
- References
- 49
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 2 · 2023: 10 · 2022: 5 · 2021: 7 · 2020: 5 · 2019: 14 · 2018: 10 · 2017: 13 · 2016: 12 · 2015: 10 · 2014: 14 · 2013: 18 · 2012: 14
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Funders
- U.S. Department of Defense
- Cold Spring Harbor Laboratory
- National Cancer Institute (CA13106, P01CA013106)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- INK4a/ARF locus, p53, retinoblastoma protein, lymphomagenesis, chemoresistance, tumor suppressor, apoptosis defects, tumor invasion, p53 inactivation
- MeSH terms
- Animals, Antineoplastic Agents, Drug Resistance, Enhancer Elements, Genetic, Female, Humans, Immunoglobulin Heavy Chains, Male, Mice, Inbred C57BL, Mice, Transgenic, Mutation, Proteins, Genes, p53, Genes, myc, Lymphoma, B-Cell, Apoptosis, Mice, Knockout, Genes, p16, Tumor Suppressor Protein p14ARF, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
